Researchers at Rutgers University have reported the first instance of COVID-19 triggering a recurrence of Guillain-Barré syndrome, a rare and potentially deadly disorder in which the body’s immune ...

Reports of Guillain-Barré syndrome (GBS) following respiratory syncytial virus (RSV) vaccination in adults ages 60 and up were higher than expected, but the vaccine's benefits still outweigh any small ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The mRNA COVID-19 vaccine was safe in ...

Researchers have reported the first instance of COVID-19 triggering a recurrence of Guillain-Barré Syndrome -- a rare disorder where the body's immune system attacks nerves and can lead to respiratory ...

Dear Dr. Roach: You have written about immunocompromised people before, but what about those of us who have immune systems that overreact instead of underperform, such as with Guillain-Barre syndrome?

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine ...

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen, is a novel disease that scientists are racing to better understand. This ...